Brelovitug Wins Second Phase 3 in Hepatitis D, Setting Up 2027 FDA Filing
Mirum brelovitug met its goal in a second Phase 3 hepatitis D trial, AZURE-4: 59% combined response vs 0%. Full data, safety, caveats and the 2027 FDA filing plan.
Mirum brelovitug met its goal in a second Phase 3 hepatitis D trial, AZURE-4: 59% combined response vs 0%. Full data, safety, caveats and the 2027 FDA filing plan.
Vir’s monthly elebsiran plus tobevibart met its Phase 3 goals in chronic hepatitis delta: 44% reached undetectable virus with normal ALT at Week 48 and 79% had undetectable virus.